Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced today that it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. The AEPC, founded in 1963, is the world's largest association in congenital cardiology, with over 1,000 specialists from 32 European countries and beyond.
This year's meeting, hosted by the University of Padova, focuses on advanced cardiovascular imaging and artificial intelligence—areas where Ventripoint is driving clinical progress. Ventripoint will exhibit alongside its European distributor, AngioPro, and will showcase the latest version of its VMS+ system, VMS+ 4.0, which was purpose-built to streamline workflows and make advanced cardiac analysis accessible at the point of care.
A key focus at the booth will be the ability to track cardiac function over time in congenital heart disease (CHD) patients using VMS+. The importance of longitudinal assessment is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for ventricular function assessment.
Ventripoint's priority for 2026 is accelerating the integration of VMS+ into routine clinical practice and building better care pathways for CHD patients. According to the company, VMS+ 4.0 reduces the time required to generate assessments and provides accurate volumetric cardiac measurements equivalent to MRI from a patient's first echocardiogram. These early insights support clinical decision-making and more effective patient management across a lifetime of care.
"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of Ventripoint. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI—giving clinicians the confidence they need to manage their patients at every stage of life."
The implications of this announcement are significant for the congenital cardiology field. With CHD being a lifelong condition, the ability to obtain MRI-quality measurements from routine echocardiograms could reduce the need for more expensive and time-consuming MRI scans, potentially lowering healthcare costs and improving patient access to advanced diagnostics. For clinicians, VMS+ offers a tool that fits into existing workflows, providing quantitative data to guide treatment decisions earlier in the care journey.
Ventripoint's VMS+ product family is powered by proprietary KBR technology and is compatible with ultrasound systems from all major vendors. It holds regulatory approvals in the U.S., Europe, and Canada. The company's participation at AEPC underscores its commitment to the European market and its focus on congenital cardiology, a specialty that stands to benefit from AI-enhanced imaging.
Forward-looking statements in the release note that actual results could differ due to risks detailed in the company's management discussion and analysis available on SEDAR.
